Health & Fitness
Health and Fitness
Health and Fitness
Mon, February 20, 2012Sat, February 18, 2012Fri, February 17, 2012Thu, February 16, 2012Wed, February 15, 2012Tue, February 14, 2012Mon, February 13, 2012Sun, February 12, 2012Fri, February 10, 2012Thu, February 9, 2012Wed, February 8, 2012Tue, February 7, 2012Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
Published in Health and Fitness on Monday, February 13th 2012 at 13:13 GMT by Market Wire
Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference -- TARRYTOWN, N.Y., Feb. 13, 2012 /PRNewswire/ --
Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
TARRYTOWN, N.Y., Feb. 13, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: [ REGN ]) will webcast its presentation at the Leerink Swann 2012 Global Healthcare Conference on Wednesday, February 15, 2012. The presentation is scheduled for 9:00 a.m. Eastern Time. The session may be accessed through the Company's web site, [ www.regeneron.com ], on the 'Events and Presentations' page. An archived version of the presentation will be available for 30 days.
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets two products in the United States, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA® (aflibercept) Injection, and has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for each of these products. A regulatory application has also been submitted to FDA for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion. Phase 3 studies are in progress with EYLEA® in a third indication, with ZALTRAP® in a second indication, and with product candidate Sarilumab. Earlier-stage clinical programs are underway with nine additional product candidates. Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia. Additional information and recent news releases are available on the Regeneron web site at [ www.regeneron.com ].
Contact Information: |
|
|
|
Manisha Narasimhan, Ph.D. | Peter Dworkin |
Investor Relations | Corporate Communications |
914-847-5126 | 914.847.7640 |
SOURCE Regeneron Pharmaceuticals, Inc.
[ Back to top ] RELATED LINKS
[ http://www.regeneron.com ]
